Encysive Pharmaceuticals Announces Launch Of THELIN In United Kingdom

HOUSTON, Nov. 6, 2006 (PRIMEZONE) -- Encysive Pharmaceuticals (Nasdaq:ENCY) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium)(2) 100 mg tablets in the United Kingdom for the treatment of pulmonary arterial hypertension (PAH). The United Kingdom is the first European Union (EU) country in which Encysive is launching THELIN. The Company was granted marketing authorization for THELIN by the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist, and the first once daily oral treatment available for patients with PAH.

Back to news